Infections of the central nervous system (CNS) are infrequently diagnosed in immunocompetent patients, but they do occur in a significant proportion of patients with hematological disorders. In particular, patients undergoing allogeneic hematopoietic stem-cell transplantation carry a high risk for CNS infections of up to 15%. Fungi and Toxoplasma gondii are the predominant causative agents. The diagnosis of CNS infections is based on neuroimaging, cerebrospinal fluid examination and biopsy of suspicious lesions in selected patients. However, identification of CNS infections in immunocompromised patients could represent a major challenge since metabolic disturbances, side-effects of antineoplastic or immunosuppressive drugs and CNS involvement of the underlying hematological disorder may mimic symptoms of a CNS infection. The prognosis of CNS infections is generally poor in these patients, albeit the introduction of novel substances (e.g. voriconazole) has improved the outcome in distinct patient subgroups. This guideline has been developed by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) with the contribution of a panel of 14 experts certified in internal medicine, hematology/oncology, infectious diseases, intensive care, neurology and neuroradiology. Grades of recommendation and levels of evidence were categorized by using novel criteria, as recently published by the European Society of Clinical Microbiology and Infectious Diseases.
introduction
Infections of the central nervous system (CNS) occur in a relevant proportion of immunocompromised patients and contribute significantly to morbidity and mortality. Only limited data are available on the clinical characteristics, optimal diagnostic procedures and treatment of CNS infections in these patients, and studies on CNS infections frequently focused on specific causative agents or distinct patient subgroups such as recipients of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) [1, 2] .
This guideline focuses on patients with hematological malignancies including allo-HSCT recipients defined as 'patients with hematological disorders' hereafter. Patients with nonmalignant hematological disorders (e.g. aplastic anemia) or solid tumors are not specifically excluded albeit CNS infections are very rare in these patients and larger analyses focusing on CNS infections in these subgroups are lacking. In the first part of this guideline, an overview on epidemiology, causative agents, risk factors, pathogenesis, prophylaxis in addition to general diagnostic strategies and management of CNS infections is given. The second part focuses on distinct infectious agents. For recommendations on diagnosis and treatment of bacterial CNS infections (including tuberculous meningitis), see supplementary Material, available at Annals of Oncology online. The strengths of recommendation and levels of evidence were categorized according to the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) criteria (Table 1) [3] .
general strategies to diagnose and to treat CNS infections in patients with hematological disorders Some principal aspects regarding the management of CNS infections in patients with hematological disorders should be considered:
(i) The management of CNS infections in patients with hematological disorders requires a high level of awareness, as neurological symptoms could be nonspecific and caused by noninfectious conditions related to the underlying disease and/or side-effects of antineoplastic or immunosuppressive treatment [1, 5, 14] . (ii) While clinical presentations of CNS infections in immunocompetent hosts are broadly categorized into meningitis, meningoencephalitis, cerebritis/abscess formation and infection of intracerebral devices, diminished inflammatory responses in immunocompromised patients can lead to only subtle symptoms. Mass lesions can be blurred by rather nonspecific cerebral dysfunctions such as confusion or altered consciousness [1, 14] . Table 1 . Strength of recommendation (A) and quality of evidence (B) [3] (A) Grade Strength of recommendation Grade A AGIHO 'strongly' supports a recommendation for use Grade B AGIHO 'moderately' supports a recommendation for use Grade C AGIHO 'marginally' supports a recommendation for use Grade D AGIHO 'supports' a recommendation 'against' use (B) Level Quality of evidence I Evidence from at least one properly designed randomized, controlled trial(iii) Defined patient groups predispose for infections with certain pathogens based on their pattern of immunosuppression (defects in cell-mediated immunity versus defective humoral immunity) [18, 19] . Bacterial, fungal and viral CNS infections typically occur in neutropenic patients. Defects in T-cell immunity or in function of macrophages predispose for cerebral toxoplasmosis and cryptococcal meningitis [2, 18, 20] . (iv) Variations in the frequency of causative organisms (e.g.
Toxoplasma spp. Histoplasma capsulatum, Mycobacterium tuberculosis) due to regional endemic differences should be taken into account [21] [22] [23] .
diagnosis
Any suspicion of CNS infection should immediately trigger adequate diagnostic procedures including neuroimaging, cerebrospinal fluid (CSF) examination and, in selected cases, biopsy of focal lesions ( Figure 1 ). CSF analyses including various methods such as staining and microscopy, culturing, serological techniques and PCR assays are crucial to diagnose meningoencephalitis which is typically caused by viruses, Candida spp., bacteria or more rarely Cryptococcus spp. (Figure 1 , Table 2 ). For these CNS infections, brain biopsy is required only in selected cases. Focal lesions, typically caused by Toxoplasma or Aspergillus spp. are commonly diagnosed by histopathology of suspicious lesions. Histopathological work-up should be done using adequate staining methods such as Calcofluor white. Routine parameters in the CSF are frequently nonspecifically altered in these patients. Neuroimaging should commonly be based on magnetic resonance imaging (MRI) since it is more sensitive than computed tomography (CT) scan for diagnosis of the majority of CNS infections [102] [103] [104] [105] .
Further diagnostic methods such as positron emission tomography might help in selected patients to differentiate infectious from noninfectious CNS lesions [106] .
antimicrobial treatment
Given the dismal outcome of delayed treatment in patients with hematological disorders and CNS infection, antimicrobial treatment should be initiated promptly once collection of CSF and blood cultures has been completed ( Figure 1 ) [107] [108] [109] . After isolation and in vitro susceptibility testing of a ( potentially) causative pathogen, antimicrobial treatment should be modified accordingly. Recommendations for empiric, pre-emptive and targeted treatment are specified in Figure 1 , Table 3 and supplementary Table S1 , available at Annals of Oncology online. Directed treatment: Should be initiated immediately after isolation of a (potential) causative organism and follow the recommendations specified in Table 3 Empirical/preemptive treatment: 3 rd generation cephalosporin or meropenem + ampicillin +/-vancomycin +/-acyclovir (if viral encephalitis is suspected) Stereotactic brain biopsy/neurosurgical resection of brain lesions (if technically possible) followed by identification and resistance testing of potential causative organisms *The decision on brain biopsy/neurosurgical resection should always be made on the basis of the technical feasibility, the suspicious causative agent, and other factors (such as presence of thrombocytopenia). For example, brain biopsy might not be required to establish the diagnosis of PML in patients with typical neuroimaging findings together with a positive CSF JC virus PCR. [188, [195] [196] [197] Cidofovir (i.v., optimal dosage unclear, e.g. 5 mg/kg once weekly) CIII [198, 199] Ganciclovir (i.v., 5 mg/kg q12h) + cidofovir (i.v., e.g. 5 mg/kg once weekly) CIII [195, 200] Due to the lack of systematic data, decisions about the duration of antimicrobial treatment should be assessed individually. Hereby, the strategy of treatment (such as antimicrobial drug therapy with or without surgery), resolution of symptoms and recovery of the individual immune-status, as defined by the presence of neutropenia, hypogammaglobulinemia and graftversus-host disease should be taken in account. In patients with persisting complex immunodeficiencies, targeted antimicrobial treatment might be followed by maintenance treatment (e.g. for cerebral toxoplasmosis). To improve efficacy and minimize toxicity, therapeutic drug monitoring (TDM) might be useful for antimicrobial agents, such as 5-fluorocytosine (5-FC), voriconazole and posaconazole [BII] [229, 230] . TDM might be of particular relevance in patients with hematological disorders since impaired gastrointestinal resorption and interferences with co-medication are common in this population [230] [231] [232] .
adjunctive treatment
Adjunctive treatment may include neurosurgery, platelet transfusion and administration of corticosteroids, anticonvulsants, sedatives or antipyretics (see supplementary Material, available at Annals of Oncology online).
CNS infections related to specific causative agents parasitic CNS infections
Toxoplasma spp. belong to the most common causative agents in allo-HSCT recipients with CNS infections [1, 6] . However, other parasitic CNS infections such as malaria, microsporidiosis, leishmaniasis, trypanosomiasis or helminthic infections have also been described in immunocompromised hosts [233] .
Toxoplasma spp. Mental abnormalities, fatigue and fever are frequent clinical symptoms in allo-HSCT recipients with cerebral toxoplasmosis [234] . Neuroimaging by MRI frequently shows typical hypo-/isointensities mainly in the basal ganglia and the frontal lobe (supplementary Figure S1 , available at Annals of Oncology online) [105] . Higher sensitivity of MRI compared with CT scan has been demonstrated in a comparative retrospective analysis [104, 105] . However, typical nodular or ring enhancement surrounded by edema was visible by MRI in only 60% of allo-HSCT patients [235] . Besides neuroimaging, diagnosis of cerebral toxoplasmosis is based on demonstration of tachyzoites or cysts in the CSF [ Figure S2 , available at Annals of Oncology online) [238, 239] . A definitive diagnosis frequently requires biopsy of suspicious lesions and demonstration of typical septate hyphae [A] [30, 31] . Several studies indicate that detection of CSF galactomannan [B] or the PCR assay [B] might also be useful to diagnose CNS aspergillosis [32] [33] [34] [35] 37] . In Aspergillus meningitis, CSF galactomannan might be detected in almost 90% of cases, whereas fungal cultures are positive in ∼30% [32] . CSF fungal cultures are usually negative in patients with Aspergillus CNS infection other than meningitis [32] .
Voriconazole is the drug of choice in CNS aspergillosis, as this azole displays sufficient penetration into the CNS [ [127] [128] [129] . Posaconazole has been used in a series of patients with CNS infections caused by various fungi, including three assessable patients with CNS aspergillosis [DIII] [132] . Caspofungin has demonstrated some activity in a mouse model exploring CNS aspergillosis, but clinical data on the use of echinocandins in CNS aspergillosis are scarce [130, 131] . Some animal model data suggest that combination therapy (e.g. voriconazole with L-AmB) might be beneficial, but meaningful clinical data are not available to recommend the use of combination therapies in CNS aspergillosis [DIII] [241, 242] .
Intrathecal or intralesional administration of AmB has been repeatedly been applied to patients with CNS aspergillosis, but published data are limited to case reports [DIII] [243, 244] . In addition, intrathecal D-AmB could cause chemical arachnoiditis and it is unlikely that sufficient drug concentration is achieved in infected brain tissues [245] . Adjunctive corticosteroid therapy could reduce mass effects and brain edema, but should be avoided whenever possible due to its deleterious effects in invasive fungal infections [246] . If corticosteroid therapy is unavoidable, prednisolone should be preferred over dexamethasone, as dexamethasone is associated with low voriconazole levels (S. Schwartz, personal communication).
Neurosurgical interventions could facilitate diagnostic confirmation and contribute to a successful outcome, likely by removing infarcted areas with poor drug penetration [BII u ] [117, 118, 136, 137] .
Candida spp.. Candida CNS infections typically present as meningoencephalitis or as ventriculitis associated with foreign bodies such as shunts or, rarely, as brain abscesses. Candida microabscesses could be discovered at autopsy, while CT and CSF analysis not always show clearly pathological findings in this situation [44] . Neuroimaging might show hydrocephalus in Candida meningitis and MRI is considered to be more sensitive than CT scan [44, 147] . In the case of Candida meningitis, yeasts can be detected by CSF staining in ∼40% and in ∼40%-80% by fungal cultures [A] [44, 45] . The PCR technique as well as the detection of (1 → 3)-β-D-Glucan or the Candida mannan antigen might also be useful to diagnose Candida meningitis from CSF, but these methods are not yet considered as clinical routine procedures [C] [38, 46, 47, 49] .
Most data on the treatment of Candida CNS infection are derived from pediatric patients. The use of D-AmB with 5-FC has been suggested as the optimal initial therapy for many years due to the excellent CSF penetration of 5-FC, the documented synergism of both compounds in vitro and in vivo and their documented clinical activity in Candida infections [44, 150] . The rationale for the use of L-AmB is mainly reasoned by studies in experimental Candida meningoencephalitis and clinical data from preterm newborns [140, 141, 247, 248] . Since L-AmB has an improved toxicity profile compared with D-AmB, the combination of L-AmB and 5-FC should be preferred to treat Candida CNS infections [BIII] . Fluconazole, alone or in combination with 5-FC, may be used as an oral consolidation therapy [BIII] . Voriconazole is a reasonable therapeutic option for Candida CNS infection [CIII] [145, 249] . Animal models suggest the potential usefulness of the echinocandins in Candida CNS infection, although higher doses might be required (as studied for micafungin) [151] . Clinical data are limited to case reports; thus this approach cannot be recommended for routine use yet [DIII] [152] . Any indwelling device such as a ventricular drain or a central venous line should be removed in invasive Candida infection [BIII] [250, 251] .
mucorales. Mucormycosis is a rare opportunistic infection mainly caused by Rhizopus spp. and Mucor spp. [9, 156] . The brain might be involved in a disseminated infection or by infiltration from adjacent rhino-sinu-orbital regions [8-10, 154, 156] . Clinical symptoms such as facial pain or swelling may be nonspecific but are frequently present in patients with rhinocerebral mucormycosis [158] . The CT scan frequently reveals characteristic bone destruction of the paranasal sinuses, the hard palate or adjacent structures [252] . The diagnosis should always be confirmed by a histopathological examination and/or culturing of tissue specimens [A] . Histopathological examination of infected tissue typically shows the irregular fungal hyphae with wide-angle branching, in addition to tissue necrosis and fungal angioinvasion [53] . PCR assays using infected tissue specimens [B] or blood [C] have also been evaluated to diagnose mycormycosis [54, 55, 57] . However, these methods are not standardized yet.
Single-agent L-AmB is recommended to treat mucormycosis [AII t,u ], but some experts suggest a primary polyene-caspofungin combination [CIII] [158] [159] [160] . Immediate surgical resection of necrotic tissue may be crucial in addition to antifungal treatment in invasive mucormycosis [AII t,u [167] [168] [169] [170] . Hyperbaric oxygen has been investigated as primary or salvage treatment of mucormycosis [254] [255] [256] . This approach is available only in some centers and there are no larger trials confirming its benefit [CIII].
Cryptococcus spp. Reports from human immunodeficiency virus (HIV)-negative patients with hematological disorders and infection with Cryptococcus spp. are limited [257, 258] . Neuroimaging by MRI may show dilated Virchow-Robin spaces, cyst-like structures and granuloma of the choroid plexus [259] . [132, 180, 183] . Cryptococcus spp. are in vitro resistant to echinocandines [184] . Thus, these agents do not play a role in the treatment of cryptococcal meningitis [DIII] . Reducing the CSF opening pressure (e.g. by repetitive lumbar punctures) is useful besides anti-infectious drug therapy in selected patients with cryptococcal meningitis [BII] [172, 261] .
viruses
Herpes viruses, in particular herpes simplex virus (HSV), Epstein-Barr virus (EBV) and human herpes virus-6 (HHV-6) are prevailing in allo-HSCT recipients [2, 73] . Viral CNS infections typically present as meningoencephalitis, but strokes-e.g. caused by varicella zoster virus (VZV)-or leukoencephalopathy (e.g. JC virus-associated PML) might occur [18] . The diagnosis of viral CNS infections is usually made by CSF PCR together with neuroimaging, preferably MRI [2, 109, 262] .
CSF viral PCR assays have an excellent sensitivity and specificity of 90%-100% for the majority of virus types [64, 65] . Thus, CSF PCR is regarded as a 'gold standard' for diagnosis of viral CNS infections [A] . However, studies comparing viral isolation from autopsy samples or brain-biopsy specimens-the former reference standard-with PCR are available only for few viruses such as HSV or cytomegalovirus (CMV) [64, 65, 70] . CSF virus PCR might initially be false-negative and the probability of a positive PCR increases when there is a time frame of 3-14 days between onset of symptoms and lumbar puncture [263] . herpes simplex virus. The incidence of HSV encephalitis is relatively low in patients with hematological disorders and there have been few cases published which mainly include allo-HSCT recipients [2, 73, 264] .
CSF PCR is a rapid method to diagnose HSV encephalitis with high sensitivity and specificity (both >90%) [A] [64, 65] . Detection of CSF HSV antibodies is not a reliable diagnostic tool for HSV encephalitis since the sensitivity and specificity is only 75%-85% and 60%-90%, respectively [C] [66] . Detection of CSF HSV antigen has a sensitivity and a specificity of ∼90% and might be of value as an adjunctive test [C] [66, 67] . CSF viral cultures are frequently negative in HSV encephalitis [D] [68] . Cerebral MRI typically shows abnormalities in the medial and inferior temporal lobe, the insula and the cingulate (supplementary Figure S3 , available at Annals of Oncology online) [265] . However, cerebral MRI might also be inconspicuous in allo-HSCT recipients with HSV encephalitis [2, 73] .
HSV encephalitis should immediately be treated with aciclovir [AII t ] [73, [185] [186] [187] .
In rare cases of aciclovir resistance, foscarnet may be administered [CIII] [190] . Patients with HSV encephalitis have a good overall prognosis, but a large proportion of patients (up to 70%) recover with neurological sequelae [2, 187] .
cytomegalovirus. CMV CNS disease is typically characterized by ventriculo-encephalitis, retinitis and polyradiculopathy [195, 266, 267] . CSF CMV PCR has a high sensitivity (up to 100%) for the diagnosis of CMV CNS disease [A] [69] [70] [71] [72] . Detection of CMV in CSF by viral cultures might only be used as an adjunctive test since it has a low sensitivity of ∼20% [C] [69, 72] .
CMV CNS disease is commonly treated with ganciclovir or foscarnet [AIII] [188] . Some authors recommend a combination of both agents [BIII] [188, [195] [196] [197] . Cidofovir as single agent or in combination with foscarnet or ganciclovir might be used for salvage treatment [CIII] [195, 200, 201] . Some reports support the use of leflunomide to control CMV disease [CIII] [201, 268, 269] . There are no systematic data showing a benefit of the routine administration of CMV hyperimmunoglobulin in patients with hematological disorders and CMV disease.
Epstein-Barr virus. Except for patients with allo-HSCT, EBV disease other than infectious mononucleosis is a rare entity. Diagnosis of EBV meningoencephalitis is based on CSF PCR [A] [2, [73] [74] [75] . However, brain-biopsy-proven EBV meningoencephalitis in conjunction with a negative CSF EBV PCR has been reported [76] .
A reduction of immunosuppression should be attempted whenever possible in patients with EBV disease or infection [AIII] [188] . The role of rituximab in EBV disease (i.e. presence of EBV organ involvement) remains to be elucidated despite the fact that first experiences suggest that pre-emptive treatment of EBV infections (i.e. EBV reactivation only) might reduce the incidence of post-transplant lymphoproliferative disorder [270] . Likewise, it remains unclear whether antivirals are beneficial in EBV disease [188] . Ganciclovir, valganciclovir or foscarnet might be used to treat EBV meningoencephalitis [BIII] and there are few case reports on the potential efficacy of aciclovir in this situation [CIII] [188, [202] [203] [204] [205] [206] [207] [208] [209] .
human herpes virus-6. HHV-6 CNS disease (mainly encephalitis) has rarely been described except in allo-HSCT recipients [2, 7, 77, 78, 210] . HHV-6 encephalitis typically [77, 78] . However, it should be noted that HHV-6 DNA might be detected in CSF in a significant proportion of asymptomatic allo-HSCT recipients [79] . CSF analysis might show elevated protein levels and, more rarely pleocytosis [2, 77] . Imaging abnormalities which typically involve the temporal lobe are more likely visible in MRI than in CT scan (supplementary Figure S4 , available at Annals of Oncology online) [2, 77] . Despite this, cerebral MRI might be normal in the early phase of HHV-6 meningoencephalitis in allo-HSCT recipients [2, 77, 78] . Ganciclovir or foscarnet could be used as first-line therapy for HHV-6 meningoencephalitis [AIII] [7, 8, [210] [211] [212] [213] . Cidofovir can be administered as second-line treatment [CIII] [215] . varicella zoster virus. Primary VZV infection (chickenpox) occurs rarely in patients with hematological disorders, since VZV-seronegativity in adulthood is rare (∼5%). In VZVseropositive recipients, VZV disease after allo-HSCT most commonly manifests as dermatomal herpes zoster but a VZV meningoencephalitis may occur [2, 216, 217] . Small patient series indicate that CSF PCR has a similar good sensitivity and specificity for diagnosis of VZV meningoencephalitis as for other herpes viruses [A] [80] [81] [82] . The CSF VZV viral load determined by PCR might correlate with the severity and the duration of VZV meningoencephalitis [218] . Diagnosis of VZV meningoencephalitis may be confirmed by serological tests such as detection of intrathecal VZV glycoprotein E [272] . Rash and CSF pleocytosis might be absent in patients with cerebral VZV vasculopathy (such as strokes). In this situation, detection of CSF anti-VZV IgG antibodies might have a higher sensitivity than CSF VZV PCR [B] [83] .
VZV CNS infections can be successfully treated with aciclovir [AIII] [2, 73, 218] . However, aciclovir resistance could occur and there are case reports on fatal CNS meningoencephalitis in allo-HSCT recipients despite early therapy with high-dose aciclovir [216] . These patients might benefit from a combination of aciclovir and foscarnet [CIII] [219] .
JC virus. JC virus-related PML typically affects severely immunocompromised hosts such as Acquired Immune Deficiency Syndrome (AIDS) patients or allo-HSCT recipients [2, 273] . CNS biopsy of suspicious lesions is required for definitive diagnosis of PML [A] . The typical triad (demyelination, bizarre astrocytes and enlarged oligodendroglial nuclei) can frequently be demonstrated by histopathological work-up in biopsies which might be combined with tissue and CSF JC virus (dual qualitative-quantitative nested) PCR [A] [86, 88, 89] . MRI typically shows abnormalities in the posterior white matter without contrast enhancement (supplementary Figure S5 , available at Annals of Oncology online) [274] . The diagnosis of PML could also be established without CNS biopsy in immunocompromised patients with typical clinical symptoms and characteristic findings by neuroimaging together with a positive CSF JC virus PCR [A] [86] .
Immune reconstitution seems to be crucial for treatment of PML, as suggested by the observation that the incidence of PML could be markedly reduced in AIDS patients by the introduction of highly active antiretroviral therapy (HAART) [273, 275] . However, PML might develop or worsen (in the case of preexisting PML) at the beginning of HAART (PML-immune reconstitution inflammatory syndrome, IRIS) [273, 275, 276] . PML-IRIS has also been described during withdrawal of agents which are associated with the occurrence of PML, such as natalizumab [277] .
Immunosuppressives should be reduced in allo-HSCT recipients with PML whenever possible [AIII] [12] . Treatment with cidofovir may be beneficial in some patients with PML [2, 278, 279] . In contrast, other allo-HSCT recipients as well as a larger series of 370 AIDS patients with PML did not improve after treatment with cidofovir [DII t,u ] [12, 221] . Several experimental approaches such as adoptive T-cell therapy or administration of interleukin-2, mefloquine or mirtazapine have been tested as a treatment option for PML [12, [278] [279] [280] . Since none of them has clearly shown to be effective in larger series of patients they are recommended within experimental protocols only [DIII] .
conclusions Diagnosis of CNS infections remains a great challenge in patients with hematological disorders since symptoms might both be masked and be mimicked by other conditions such as metabolic disturbances or consequences from antineoplastic treatment. Thus, awareness of this complication is crucial and any suspicion of a CNS infection should lead to timely and adequate diagnostics and treatment to improve the outcome in this population. references
